Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV)

Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.

Publication types

  • News
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus* / drug effects
  • Betacoronavirus* / genetics
  • Betacoronavirus* / pathogenicity
  • Coronavirus Infections / drug therapy*
  • Drug Repositioning*
  • HIV Infections / drug therapy
  • Hepatitis B / drug therapy
  • Hepatitis C / drug therapy
  • Humans
  • Influenza, Human / drug therapy
  • Interferon-alpha / pharmacology
  • Interferon-alpha / therapeutic use
  • Middle East Respiratory Syndrome Coronavirus / drug effects
  • Middle East Respiratory Syndrome Coronavirus / genetics
  • Middle East Respiratory Syndrome Coronavirus / pathogenicity
  • Nucleosides* / pharmacology
  • Nucleosides* / therapeutic use
  • Pneumonia, Viral / drug therapy*
  • Polyethylene Glycols / pharmacology
  • Polyethylene Glycols / therapeutic use
  • Protease Inhibitors* / pharmacology
  • Protease Inhibitors* / therapeutic use
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • SARS Virus / drug effects
  • SARS Virus / genetics
  • SARS Virus / pathogenicity
  • Spike Glycoprotein, Coronavirus / drug effects

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Nucleosides
  • Protease Inhibitors
  • Recombinant Proteins
  • Spike Glycoprotein, Coronavirus
  • remdesivir
  • Polyethylene Glycols
  • Adenosine Monophosphate
  • Alanine
  • peginterferon alfa-2a

Supplementary concepts

  • COVID-19
  • COVID-19 drug treatment
  • severe acute respiratory syndrome coronavirus 2